Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trialAndreas Glenthøj, Wilma Barcellini, Satheesh Chonat et al.|The Lancet Haematology|2022Cited by 49
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Wally R. Smith, Lucas Otieno et al.|The Lancet Haematology|2024Cited by 25
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell DiseaseJoanna Howard, Swee Lay Thien, Abdulafeez Oluyadi et al.|Blood|2021Cited by 4